2 June 2020 - Vaccines are widely expected to offer the best way out of the COVID-19 pandemic. 

But they won’t help unless they’re safe and effective, making it essential that only rigorously tested approaches reach the public. Recent history suggests there is reason to be concerned.

On 18 May, the biotechnology company Moderna reported preliminary results from its first-in-human coronavirus vaccine trial. Releasing limited information — though to great fanfare — Moderna said the first eight volunteers with available results had developed neutralizing antibodies at levels similar to those in recovering patients.

Read Washington Post article